Ravagalimab
Ravagalimab (ABBV-323) is a CD40 antagonist (EC50: 3.7 nM) . Ravagalimab can be used for research of Crohn's disease[1].
Product Specifications
CAS Number
[2050816-56-1]
Product Name Alternative
ABBV-323
UNSPSC
12352203
Target
TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ravagalimab.html
Purity
99.31
Solubility
10 mM in DMSO
Smiles
[Ravagalimab]
Molecular Weight
(146.04 kDa)
References & Citations
[1]Argiriadi MA, et al. CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019 Aug 5;20 (1) :29. |[2]Yu X, et al. Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity. Cancer Cell. 2020 Jun 8;37 (6) :850-866.e7.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Isoform
TNFRSF5/CD40
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
